Ciusss de L'Est de l'Île de Montréal   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Montreal Canada (2015)

Organization Overview

First Clinical Trial
2016
NCT02924987
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Centre intégré de santé et de services sociaux de l'Est-de-l'Île-de-Montréal | CIUSSS-Centre-Sud-de-l'Île-de-Montréal | Ciusss de L'Est de l'Île de Montréal | CIUSSS de l'Est de Montreal, Hopital Maisonneuve Rosemont | CIUSSS du Nord-de-l'Île-de-Montréal | CIUSSSE-CHUS | CIUSSS Est de l'ile de Montreal | CIUSSS Est de l'île de Montréal

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Disease (Phase 2)

Edema (Phase 4)

Endometrial Neoplasms (Phase 3)

Head and Neck Neoplasms (Phase 3)

Hematologic Neoplasms (Phase 2)

Lymphoma (Phase 2)

Macular Edema (Phase 4)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Neuroblastoma (Phase 2)

Nociceptive Pain (Phase 4)

Preleukemia (Phase 2)

Recurrence (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 29
  • # of Trial APIs: 35